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1. Introduction
The rat conditioned avoidance response (CAR) model is 
a commonly used preclinical test for antipsychotic activity 
(Arnt, 1982). All currently used antipsychotics at clinically rel-
evant doses selectively disrupt avoidance response to a condi-
tioned stimulus (CS, e.g. white noise) without altering escape 
response to an unconditioned stimulus (US, e.g. footshock). 
This feature has been effectively used to identify potential an-
tipsychotic drugs, to differentiate antipsychotic drugs from 
other classes of psychotropic drugs, and to predict the clini-
cal potency of antipsychotic drugs and (Arnt, 1982; Bignami, 
1978; Cook and Davidson, 1978; Janssen et al., 1965; Kurib-
ara and Tadokoro, 1981; Shannon et al., 1999; van der Heyden 
and Bradford, 1988; Wadenberg and Hicks, 1999). Therefore, 
understanding the nature of antipsychotic-induced avoidance 
disruption may shed light on the behavioral and neurobiolog-
ical mechanisms of antipsychotic action in the treatment of 
psychosis.
In recent years, we have reported several studies that ex-
amined the behavioral mechanisms of antipsychotic effect in 
the CAR model (Li et al., 2004, 2007, 2009a, 2009b, 2010; Mead 
and Li, 2010). Our overall results suggest that typical and atyp-
ical antipsychotic drugs disrupt avoidance via two separate 
mechanisms: (1) attenuating the motivational salience of the 
CS and (2) providing an interoceptive drug cue that allows the 
decreased salience of the CS to be maintained over time. The 
attenuation action on motivational salience of the CS refers to 
the weakening effect of antipsychotic treatment on the ability 
of the CS to instigate an active motor response from an organ-
ism. One interesting finding in support of this action comes 
from our recent study (Li et al., 2009b), in which we exam-
ined olanzapine and risperidone in a modified avoidance con-
ditioning procedure involving two types of CS (CS1: a white 
noise and CS2: a pure tone). These two CSs varied in their sa-
lience and ability to predict the occurrence of the US (the 
CS1 was paired with the US in every trial, whereas the CS2 
was paired with the US in only half of the trials). We found 
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Abstract
Suppression of conditioned avoidance response is a preclinical behavioral index of antipsychotic activity. Previ-
ous work shows that olanzapine and risperidone disrupt avoidance response elicited by a less salient conditioned 
stimulus (CS2) to a greater extent than avoidance elicited by a more salient stimulus (CS1), suggesting that antipsy-
chotic drugs may have a weakening action on motivational salience of stimuli. In the present study, we further exam-
ined this mechanism of antipsychotic action, focusing on the possible impact of baseline difference of CS1 and CS2 
response rates on the avoidance-disruptive effect of olanzapine and risperidone. Rats were first trained to acquire 
avoidance responding in a procedure in which the number of CS2 trials (i.e. 20) was twice the number of CS1 trials 
(i.e. 10), but the percentage of CS2-shock pairing was set at 25% lower (15 trials out of 20) than the percentage of CS1-
shock pairing (20 trials out of 20). They were then tested daily under olanzapine (0.5 and 1.0 mg/kg, sc) or risperi-
done (0.33 and 1.0 mg/kg, sc) for 5 consecutive days. Repeated olanzapine and risperidone treatment dose-depend-
ently disrupted avoidance responding to both CS1 and CS2. Both drugs at the high dose disrupted the CS2 avoidance 
to a greater extent than the CS1 avoidance. In the final challenge test, rats previously treated with olanzapine were 
tested under risperidone (0.33 mg/kg), whereas rats previously treated with risperidone were tested under olanzap-
ine (0.5 mg/kg). Results show that rats previously treated with risperidone 1.0 mg/kg group made significantly fewer 
avoidance responses than the vehicles under olanzapine at 0.5 mg/kg. These findings confirm that olanzapine and 
risperidone disrupt avoidance response primarily by selectively attenuating the motivational salience of the CS. The 
present study also suggests that there is a generality of antipsychotic drug experience that is mediated by a shared in-
teroceptive drug state mechanism.
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that both drugs had a stronger disruptive effect on a less sa-
lient CS2-elicited avoidance than a highly salient CS1-elicited 
avoidance. Although this result is consistent with our moti-
vational salience attenuation hypothesis, there are alternative 
explanations. For example, this differential action may result 
from the different baseline levels of CS1 and CS2 avoidance. 
In the previous study (Li et al., 2009b), the mean CS1 avoid-
ance (about 95% of 20 trials) was significantly higher than the 
mean CS2 avoidance (~ 50% of 10 trials) on the pre-drug day. 
This difference in avoidance responding rate at baseline could 
have contributed to the greater disruptive effects of antipsy-
chotic drugs on CS2 avoidance, independent of motivational 
salience of CS1 and CS2. There are many published examples 
which demonstrate that differences in scheduling of events 
and rate of behavioral responding can determine the direc-
tion and magnitude of the behavioral effects of drugs (Barrett, 
2002; Barrett et al., 2008; Dews, 1976; McMillan and Katz, 2002; 
Spealman et al., 1983). Thus, the primary purpose of the pres-
ent study was to further investigate the motivational salience 
attenuation action of olanzapine and risperidone and to distin-
guish between these two alternative interpretations (“motiva-
tional salience” versus “different baseline response”). In doing 
so, we created a new CAR procedure in which the number of 
CS2 trials (i.e. 20) was twice the number of CS1 trials (i.e. 10), 
but the percentage of CS2–US (shock) pairing was set at 25% 
(15 trials out of 20) lower than the percentage of CS1–US shock 
pairing (20 trials out of 20). Under this condition, the CS1 was 
still more salient than the CS2, but the baseline CS2 avoid-
ances were higher than CS1 avoidances. If olanzapine and ris-
peridone were to decrease CS2 avoidance to a greater extent 
than CS1 avoidance, it would provide additional evidence in 
support of the motivational salience interpretation.
The secondary purpose was to examine the interoceptive 
drug state mechanism. Our previous work shows that anti-
psychotic drugs haloperidol and olanzapine share a common 
“antipsychotic” interoceptive drug state, as evidenced by the 
findings that rats previously treated with haloperidol (or olan-
zapine) showed a stronger response to the avoidance-disrup-
tive effect of olanzapine (or haloperidol) than drug-naïve rats 
(Li et al., 2007; Mead and Li, 2010). The present study exam-
ined the possible shared interoceptive drug state between 
olanzapine and risperidone and also investigated whether 
prior experience with one drug (e.g. olanzapine) could be 
transferrable to another drug (e.g. risperidone).
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats (226–250 g upon arrival, 
Charles River, Portage, MI) were housed two per cage, in 
48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages 
under 12-h light/dark conditions (light on between 6:30 am and 
6:30 pm). Room temperature was maintained at 22 ± 1 °C with 
an averaged humidity around 45%. Food and water were avail-
able ad libitum. Animals were allowed at least one week of habit-
uation to the animal facility before being used in experiments. 
All procedures were approved by the Institutional Animal Care 
and Use Committee at the University of Nebraska-Lincoln.
2.2. Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and 
manufactured by Med Associates (St. Albans, VT) were used. 
Each box was housed in a ventilated, sound-insulated isolation 
cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 
64 cm long, 30 cm high (from grid floor), and 24 cm wide, and 
was divided into two equal-sized compartments by a partition 
with an arch style doorway (15 cm high × 9 cm wide at base). A 
barrier (4 cm high) was placed between the two compartments, 
so the rats had to jump from one compartment to the other. 
The grid floor consisted of 40 stainless-steel rods with a diam-
eter of 0.48 cm, spaced 1.6 cm apart center to center, through 
which a scrambled footshock (US, 0.8 mA, maximum duration: 
5 s) was delivered by a constant current shock generator (Model 
ENV-410B) and scrambler (Model ENV-412). Illumination was 
provided by two houselights mounted at the top of each com-
partment. The CSs (either a 76 dB white noise CS1 or an 85 dB 
2800 Hz pure tone CS2) were produced by a speaker (ENV 224 
AMX) mounted on the ceiling of the cubicle, centered above the 
shuttle box. Background noise (approximately 74 dB) was pro-
vided by a ventilation fan affixed at the top corner of each isola-
tion cubicle. All training and testing procedures were controlled 
by Med Associates programs running on a computer.
2.3. Drugs
Olanzapine (OLZ) and risperidone (RIS) (gifts from NIMH 
Chemical Synthesis and Drug Supply Program) were dis-
solved in 1.0% glacial acetic acid in distilled water. We chose 
olanzapine at 0.5 and 1.0 mg/kg and risperidone at 0.33 and 
1.0 mg/kg because these doses are effective in producing a ro-
bust dose-dependent disruption of avoidance responding (Li 
et al., 2007; Li et al., 2009b), and both drugs at these doses give 
rise to clinically comparable levels of striatal D2 occupancy 
(60–70%) (Kapur et al., 2003).
2.4. Procedure
Forty-eight male Sprague–Dawley rats (226–250 g upon ar-
rival, Charles River, Potage, MI, USA) were used. After 2 days 
of shuttle box habituation, all rats were trained daily over ten 
consecutive days in the modified two-way avoidance con-
ditioning task for a total of 10 sessions. Each training session 
consisted of 30 trials. Ten trials (CS1 trials) used a 10 s 76 dB 
white noise as the CS with its termination immediately fol-
lowed by a shock (0.8 mA, maximum duration: 5 s) if the rats 
did not make an avoidance response. The remaining 20 trials 
(CS2 trials) used a pure tone (10 s, 2800 kHz, 85 dB) as the CS. 
In 15 CS2 trials, the CS2 was followed by the shock if the rat 
failed to respond to the CS2; whereas, in the remaining 5 trials, 
it was not. The 10 CS1 trials were randomly intermixed with 
the 20 CS2 trials. During each trial, if a subject moved from 
one compartment into the other within the 10s of CS presenta-
tion, that CS was immediately terminated, the shock was pre-
vented and this shuttling response was recorded as avoidance 
(termed CS1 avoidance or CS2 avoidance). If the rat remained 
in the same compartment for more than 10 s and made a cross-
ing upon receiving the footshock, this response was recorded 
as escape. If the rat did not respond during the entire 5 s pre-
sentation of the shock, the trial was terminated and escape fail-
ure was recorded. At the end of the training session period, 39 
rats had reached training criterion (≥ 7 CS1 avoidances and 
at least one CS2 avoidance in the last two training sessions). 
They were first matched on avoidance performance on the last 
training day to create blocks of rats (n = 4–5 rats/block) that 
were approximately equal in performance. Within each block, 
they were then randomly assigned to one of five groups: vehi-
cle control (VEH, n = 11), RIS 0.33 mg/kg (n = 7), RIS 1.0 mg/
kg (n = 7), OLZ 0.5 mg/kg (n = 7) and OLZ 1.0 mg/kg (n = 7). 
They were then subjected to 5 consecutive days of repeated 
VEH, RIS, or OLZ testing. On each test day, rats were injected 
with VEH (sterile water), RIS (0.33 or 1.0 mg/kg) or OLZ (0.5 
or 1.0 mg/kg) subcutaneously (sc) 1 h before being placed in 
the apparatus. One day after the last drug test, all rats were 
retrained drug-free in two sessions to bring their avoidance 
back to the pre-drug level. A final drug challenge test was con-
ducted 24 h after the last retraining session to assess the pos-
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sible shared interoceptive drug state and interchangeability 
between OLZ and RIS treatment sensitization (Li et al., 2007; 
Mead and Li, 2010). During the test, rats in the VEH group 
were randomly assigned into two subgroups and injected with 
OLZ 0.5 mg/kg (n = 5) or RIS 0.33 mg/kg (n = 6). Rats in the 
two OLZ groups were all injected with RIS 0.33 mg/kg, and 
rats in the two RIS groups were injected with OLZ 0.5 mg/kg. 
These challenge doses were chosen because they have been 
demonstrated to be effective doses in revealing prior antipsy-
chotic treatment effect (Li et al., 2010; Mead and Li, 2010). The 
same CAR procedure used during training was used through-
out the drug testing phase.
2.5. Statistical analysis
Avoidance response data from the training sessions were 
expressed as the mean number of avoidance responses and per-
cent CS1 (number of avoidances divided by 10) and CS2 (num-
ber of avoidances divided by 20) avoidance. As done in our 
previous work (Li et al., 2009b), avoidance response data from 
the drug test sessions were expressed as the percent avoidance 
on each drug test session relative to each rat’s own avoidances 
made on the last training (10th) day (% avoidance = number of 
avoidance in any drug session / number of avoidance on the 
10th training day). This measure better accounted for the dif-
ferences in the baseline number of CS1 (max: 10 trials) and CS2 
(max: 20) trials as well as individual differences at baseline. 
Data from the final challenge test was expressed as mean num-
ber of avoidance responses. Data from the five drug test ses-
sions were analyzed using a two-way mixed-design analysis 
of variance (ANOVA) with the between-subjects factor being 
drug treatment and the within-subjects factors being test ses-
sion and type of trials (i.e. CS1 or CS2 avoidance). Individual 
one-way ANOVAs were used to detect group differences on 
CS1 and CS2 avoidances separately on each drug test session 
and two retraining sessions. Data on the final olanzapine and 
risperidone challenge sessions were analyzed separately using 
one-way ANOVAs. CS1 and CS2 avoidances were also exam-
ined separately. A conventional two-tailed level of significance 
at the 5% level was required.
3. Results
3.1. CAR training phase: CS1 avoidance was acquired faster 
than CS2 avoidance
Throughout the 10 training sessions, avoidance response 
to the CS1 and CS2 showed a progressive increase across ses-
sions (Figure 1). A two-way mixed-design ANOVA on the 
number of avoidances indicated a main effect of session, F(9, 
342) = 80.877, p < 0.001, type, F(1, 38) = 90.138, p < 0.001, and a 
significant session × type interaction, F(9, 342) = 48.433, p < 0.001. 
A similar analysis on the percent avoidance revealed a similar 
main effect of session and type, but no session × type interac-
tion, F(9, 342) = 1.591, p = 0.116. Inspection of the training data 
indicated that even the daily mean numbers of CS2 avoidance 
were higher than CS1 avoidance (Figure 1A), the mean percent 
CS1 avoidance was higher than CS2 avoidance (Figure 1B), con-
firming that the CS2 stimulus was indeed less salient in instigat-
ing avoidance response than the CS1. This result was expected 
from the experimental design in which only 75% of the CS2 tri-
als (15 out of 20) were followed by shock, whereas all 10 CS1 tri-
als were followed by shock if the rats failed to respond.
3.2. Drug testing phase: olanzapine and risperidone disrupted 
CS2 avoidance to a greater extent than CS2 avoidance
As can be seen in Figure 2, across the 5 drug test ses-
sions, the VEH-treated rats maintained their levels of CS1 and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CS2 avoidance throughout the sessions, whereas the RIS 
and OLZ rats showed a dose-dependent and progressive de-
cline in both CS1 and CS2 avoidance responding. A two-way 
mixed-design ANOVA revealed a main effect of drug treat-
ment, F(4, 34) = 56.089, p < 0.001, test session, F(4, 136) = 6.050, 
p < 0.001, and trial type, F (1, 34) = 9.923, p = 0.003. The interac-
tions between drug treatment and test session, F(16, 136) = 1.993, 
p = 0.018, and between drug treatment and trial type, F(4, 
34) = 2.791, p = 0.042 were also significant, suggesting that 
OLZ and RIS had a differential effect on different types of 
avoidance trials across the drug test sessions.
For the CS1 trials, one-way ANOVAs involving all the 
groups revealed a main group effect on every day, F (4, 
34) = 26.591–35.484, ps < 0.001. Tukey post hoc tests showed 
that the two high-dose groups (i.e. OLZ 1.0 mg/kg and RIS 
1.0 mg/kg) differed significantly from the vehicle group on 
every drug day, ps < 0.011. The RIS 0.33 mg/kg group differed 
from the VEH group from day 2 to day 5, ps < 0.035, whereas 
the OLZ 0.5 mg/kg group did not differ from the VEH group 
on any of the drug test days, ps > 0.184. The RIS 1.0 mg/kg 
group had a significantly lower avoidance response among 
the four drug groups. It differed significantly from the other 
groups on days 1, 2 and 3, ps < 0.001, and from the two low-
dose groups on days 4 and 5, ps < 0.001. In addition, the OLZ 
1.0 mg/kg group also differed significantly from the OLZ 
0.5 mg/kg group on the last four test days, ps < 0.031, indicat-
ing a dose-dependent effect.
For the CS2 trials, one-way ANOVAs involving all the 
groups revealed a main group effect on every day, F (4, 
34) = 16.261–32.123, ps < 0.001. Tukey post hoc tests showed that 
all drug groups except the OLZ 0.5 mg/kg group differed sig-
nificantly from the vehicle group on every drug day, ps < 0.017. 
Once again, the RIS 1.0 mg/kg group had the greatest effect 
among the four drug groups. It differed significantly from all 
Figure 1. Acquisition of CS1 and CS2 avoidance response across the 10 
training sessions. Each point represents either mean number of avoid-
ance responses + SEM (A) or mean avoidance percent + SEM (B). The 
number of CS2 avoidance was higher than CS1 avoidance, but the per-
cent CS1 avoidance was higher than the CS2 avoidane.
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other groups on day 1, ps < 0.040, and from the two low-dose 
groups on days 2, 3 and 4, ps < 0.045, and also differed signifi-
cantly from the OLZ 0.5 mg/kg group on day 5, p = 0.003. In ad-
dition, the OLZ 1.0 mg/kg group differed significantly from the 
OLZ 0.5 mg/kg group on every test day, ps < 0.028.
3.3. Final drug challenge test: number of avoidances
During the two retraining sessions, both RIS and OLZ 
treated rats recovered quickly (data not shown). One-way 
ANOVAs on CS1 and CS2 avoidances on both sessions did not 
found any significant group difference, F(4, 34) = 0.531–1.528, 
ps > 0.215. The final challenge test was designed to examine 
the similarity between the olanzapine and risperidone-in-
duced drug state, and determine to what extent prior olan-
zapine or risperidone treatment potentiated later response to 
risperidone or olanzapine, respectively. As can be seen in Fig-
ure 3, under the RIS 0.33 mg/kg challenge condition, all three 
groups had comparable levels of CS1 and CS2 avoidance re-
sponding. One-way ANOVA revealed no significant group 
effect for CS1 avoidance, F(2, 17) = 0.037, p = 0.964 and CS2 
avoidance, F(2, 17) = 0.665, p = 0.527.
In contrast, under the OLZ 0.50 mg/kg challenge condition, 
rats that were previously treated with RIS 1.0 mg/kg made 
significantly fewer avoidance responses than rats that were 
previously treated with vehicle. One-way ANOVA revealed 
a main group effect for the CS1 avoidance, F(2, 16) = 3.867, 
p = 0.043, and the CS2 avoidance, F(2, 16) = 6.759, p = 0.007. 
Post hoc Tukey tests under each challenge condition showed 
that the RIS 1.0 mg/kg group differed significantly from the 
vehicle on these measures (all ps < 0.037). No other group dif-
ference was found.
4. Discussion
Consistent with our previous study (Li, He, 2009b), the 
present study demonstrated that repeated olanzapine or ris-
peridone treatment produced a progressive across-session de-
cline in avoidance responding to both CS1 and CS2. Olanzap-
ine and risperidone dose-dependently disrupted the CS2 (a 
less salient conditioned stimulus) avoidance to a greater ex-
tent than the CS1 avoidance. These findings together with our 
previous ones, suggest that olanzapine and risperidone dis-
rupt avoidance responding by attenuating the motivational 
salience of the conditioned stimulus (CS), while the baseline 
difference in the number of CS1 and CS2 avoidances is not a 
critical factor in determining their differential effects on CS1 
and CS2 avoidances. In addition, we showed that prior risperi-
done treatment enhanced later avoidance response to olanzap-
ine treatment, suggesting a possible shared interoceptive drug 
state and a cross-sensitization between these two drugs.
The present study was primarily designed to differentiate 
two alternative explanations of the preferential disruptive ef-
fect of antipsychotics on CS2 over CS1 avoidance responses. 
One explanation (“motivational salience attenuation”) sug-
gests that the greater disruption on CS2 avoidance is due to the 
weaker motivational salience of the CS2 relative to the CS1 (i.e. 
the ability to elicit avoidance). Another explanation (“different 
baseline response”) suggests that it is due to the lower num-
ber of CS2 avoidance than CS1 avoidance at the baseline (pre-
drug). The second explanation is consistent with a large num-
ber of reports showing that the response rate is an important 
determinant of the behavioral effects of drugs. This phenom-
enon is best known as the “rate-dependent drug effects” (Bar-
rett et al., 2008; Leander, 1975; Leander and McMillan, 1974). 
For example, it has been shown that antipsychotic drugs (e.g. 
haloperidol, clozapine, and chlorpromazine), anxiolytic drugs 
(e.g. chlordiazepoxide), and other psychoactive drugs (e.g. 
Figure 3. Effects of prior olanzapine or risperidone treatment on sub-
sequent avoidance response to a challenge test of risperidone or olan-
zapine. Rats that were previously treated with risperidone (0.33 or 
1.0 mg/kg), olanzapine (0.5 and 1.0 mg/kg) or vehicle during the drug 
testing phase were injected with olanzapine (0.5 mg/kg, s.c., −60 min) 
or risperidone (0.33 mg/kg, s.c., −60 min). Olanzapine, but not risper-
idone challenge, caused a greater decrease in avoidance responding in 
rats that were previously treated with risperidone (1.0 mg/kg). Each 
point represents either mean number of avoidance responses + SEM. 
“*” indicates a significant difference (p < 0.05) between the antipsy-
chotic group and the vehicle group.
Figure 2. Effect of repeated olanzapine (A) or risperidone (B) treatment 
on CS1 and CS2 avoidance responding. Each point represents mean 
avoidance percent + SEM relative to the last (10th) training day. The 
avoidance data from the vehicle group were plotted in both figures for 
easy comparison. Olanzapine (0.5 and 1.0 mg/kg, s.c., −60 min) and ris-
peridone (0.33 and 1.0 mg/kg, s.c., −60 min) dose-dependently disrupted 
avoidance response to both CS1 and CS2, and the disruption was pro-
gressively enhanced with repeated drug administration across the 5 daily 
test sessions. Olanzapine and risperidone had a stronger disruptive ef-
fect on CS2 avoidance than CS1 avoidance. “*” indicates a significant dif-
ference (p < 0.05) between the antipsychotic group and the vehicle group.
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amphetamine) can decrease or increase a behavioral response 
(e.g. lever-pressing, pecking, nose-poking) depending on the 
specific schedules of reinforcement (a fixed-interval schedule 
or a multiple schedule with alternating fixed-ratio and fixed-
interval components) (Barrett, 1983; Harris et al., 1978; Speal-
man et al., 1983). Our previous study could not distinguish be-
tween these two explanations because not only was the CS2 
made to be less salient than the CS1, but also the rate of CS2 
avoidance was lower than the CS1 avoidance (Li et al., 2009b). 
Thus, both explanations could account for the preferential dis-
ruptive effect of antipsychotics on CS2 over CS1 avoidance re-
sponses. In the present study, we attempted to separate these 
two factors. As we did in our previous study, we rendered the 
CS2 less salient than the CS1 by pairing the CS1 with the US 
in every CS1 trial (100%) while pairing the CS2 with the US in 
only 75% of the CS2 trials. Different from our previous study, 
we used more CS2 trials (i.e. 20) than CS1 trials (i.e. 10) in each 
training/testing session, making the rate of the CS2 avoidance 
(e.g. mean = 14 on the pre-drug day) higher than that of the 
CS1 avoidance (e.g. mean = 9 on the pre-drug day) (see Fig-
ure 1). Under this new condition, we still found that olanzap-
ine and risperidone preferentially disrupted the CS2 avoid-
ance over the CS1 avoidance. Collectively, findings from both 
studies indicate that the baseline rate of avoidance responses 
does not seem to influence the basic avoidance-disruptive ef-
fect of olanzapine and risperidone, which is in agreement with 
other reports in the literature suggesting that the effects of 
some antipsychotic drugs, such as thioridazine, chlorproma-
zine and haloperidol can be largely independent of the type 
of schedule or the type of consequent event that maintains re-
sponse (Spealman et al., 1983; Wenger, 1979). Therefore, our 
findings supported the “motivational salience attenuation” 
explanation and refuted the “different baseline response” ex-
planation. This idea is also supported by our finding that hal-
operidol-treated rats tested under a 40-trial avoidance test-
ing session showed a faster decline than those tested under 
a 10-trial session, which in turn, showed a faster decline than 
those tested under a 3-trial session (Li et al., 2007). These find-
ings, together with our previous ones (Li et al., 2009b), are also 
consistent with clinical observations that a less salient psy-
chotic thought or hallucination is easier to be corrected and 
more responsive to drug treatment than a more persistent psy-
chotic symptom (Manschreck and Khan, 2006).
As we have previously discussed (Li et al., 2009b), this idea 
that antipsychotics attenuate motivational salience of stim-
uli (e.g. decrease incentive motivation of rats) is consistent 
with the motivational salience theory of dopamine (Beninger, 
2006; Berridge, 2007; Berridge and Robinson, 1998). Accord-
ing to this theory, dopamine is centrally involved in attribut-
ing incentive salience to objects or behavioral acts. This attrib-
uted salience then facilitates approach (to positive reinforcers) 
or avoidance (to negative reinforcers) responses. It has been 
shown previously that the effects of antipsychotics in the CAR 
model are dependent upon D2 blockade in the nucleus accum-
bens (Li et al., 2010; Wadenberg et al., 1990). Therefore, the 
common behavioral mechanism shared by haloperidol, olan-
zapine, and risperidone may be attributed to their common 
antagonistic action on the D2 receptor. Accordingly, antag-
onism of D2 receptor function by haloperidol, olanzapine, or 
risperidone may inhibit the actions elicited by the CS and in-
hibit a weaker stimulus-elicited behavior to a greater extent 
than a stronger one (Ikemoto and Panksepp, 1999; Salamone 
and Correa, 2002).
The secondary aim of the present study was to examine the 
interoceptive drug state mechanism, which is hypothesized 
to play a role in maintaining the avoidance-disruptive effect 
across sessions and long-term antipsychotic drug sensitization 
(Li et al., 2007, 2009a; Mead and Li, 2010). This interoceptive 
drug state mechanism has been revealed in several ways in 
the past. In Mead and Li (2010), we reported that haloperi-
dol and olanzapine on an intermittent (on–off–on) drug treat-
ment regimen still produced a progressively enhanced disrup-
tion on avoidance responding as we observed in rats tested in 
the consecutive schedule (Li et al., 2007), despite the fact that 
they all exhibited a high level of avoidance immediately prior 
to each drug session (e.g. during the drug-free re-training ses-
sions). We also found that rats previously treated with olan-
zapine (0.5–2.0 mg/kg, sc) or risperidone (0.2–1.0 mg/kg) dur-
ing the acquisition phase of avoidance conditioning exhibited 
significantly fewer avoidance responses when they were re-
tested 3 weeks later to the same drug in comparison to rats that 
were previously treated with non-antipsychotic drugs (chlordi-
azepoxide, 10 mg/kg, citalopram 10 mg/kg, or sterile water). 
In Li et al. (2009a), we reported that pairing chlordiazepoxide 
(a cueing drug CS) with haloperidol engendered chlordiaz-
epoxide to exhibit an acquired haloperidol-like property in dis-
rupting avoidance responding. We also showed that rats pre-
viously treated with haloperidol showed a stronger response 
to the avoidance-disruptive effect of olanzapine than drug-na-
ïve rats (Li et al., 2007). Similarly, rats previously treated with 
olanzapine showed a stronger response to the avoidance-dis-
ruptive effect of haloperidol than drug-naïve rats (Mead and 
Li, 2010), suggesting that the antipsychotic drug state in-
duced by haloperidol and olanzapine share some similarities. 
The present study examined the possible shared interocep-
tive drug state between olanzapine and risperidone. We found 
an asymmetric feature between olanzapine and risperidone: 
rats previously treated with risperidone (1.0 mg/kg) showed 
a stronger response to the avoidance-disruptive effect of olan-
zapine, whereas rats previously treated with olanzapine (0.5 
and 1.0 mg/kg) showed no such enhanced response to risper-
idone. One possible reason why this happened is that risperi-
done 1.0 mg/kg caused a much stronger disruption than olan-
zapine 1.0 mg/kg (see Figures 2 & 3), thus risperidone may 
have caused a stronger sensitization-like effect than olanzap-
ine. Were a higher dose of olanzapine (e.g. 2.0 mg/kg) used, 
we may also be able to observe an enhanced response (i.e. low-
ered avoidance) to the challenge risperidone. Future work 
should employ a broader range of olanzapine and risperidone 
doses to further examine whether these drugs do share a com-
mon antipsychotic interoceptive drug state and whether prior 
experience with one drug can be transferred to another drug. 
This issue is of clinical importance because if there is such a 
shared interoceptive drug state and bidirectional exchange of 
drug sensitization between olanzapine and risperidone, clini-
cians working with patients who wish to switch from one drug 
(e.g. olanzapine ) to another drug (e.g. risperidone) may not 
need to be concerned with the possible change in antipsychotic 
efficacy during this process. However, if there is only one di-
rectional exchange of drug experience (e.g. from risperidone to 
olanzapine), clinicians may need to monitor patients’ symptom 
response to the new drug during this switching process.
Taken together, the present study used a novel avoidance 
conditioning model and showed that atypical antipsychot-
ics olanzapine and risperidone disrupt avoidance responding 
elicited by a weak stimulus to a greater extent and at a faster 
rate than one elicited by a strong stimulus, and prior antipsy-
chotic experience may be maintained over time through an in-
teroceptive drug state mechanism. To carefully extrapolate to 
clinical treatment, antipsychotic drugs may achieve their anti-
“psychotic” effect via a dual action: (a) selectively weakening 
the aberrant motivational salience of stimuli (e.g., psychotic 
thoughts or abnormal perceptions, internal and external cues); 
and (b) producing a drug interoceptive state that allows the 
weakening effect on the motivational salience of stimuli to be 
maintained over time.
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